🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to health experts.

An International Health Concern

Gonorrhoea infections are escalating worldwide, with data suggesting in excess of 82 million new cases per year. Notably increased rates are seen in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the context of rising global incidence, the spread of superbugs and the highly restricted available drugs currently available.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance showed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts hope that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This milestone signifies a significant shift in the therapy of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Testing Outcomes and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which combines a dual-drug approach. The research enrolled hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the authority to license and sell the drug in numerous regions with limited resources.

Clinicians on the front lines have shared hope. Access to a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is viewed as crucial to lessen the impact of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.